Integrated BioPharma, Inc. / Fundamentals
Income statement
- Net revenue
€46.83M - Cost of goods sold
€42.04M - Gross profit
€4.79M - SG&A expenses
€3.05M - R&D expenses
€0.00 - EBITDA
€2.82M - D&A
€1.09M - EBIT
€1.74M - Interest expenses
€0.00 - EBT
€1.78M - Tax expenses
€1.08M - Net income
€696.13K
Cash flow statement
- Net deferred tax
€1.09M - Non-cash items
-€865.86K - Changes in working capital
-€354.96K - Operating cash flow
€1.78M - Capex
€176.62K - Other investing cash flow
€0.00 - Net investing cash flow
-€176.62K - Total cash dividends paid
€0.00 - Issuance of common stock
€58.59K - Debt repayment
-€6.89K - Other financing cash flow
€15.51K - Net financing cash flow
€67.20K - Foreign exchange effects
€0.00 - Net change in cash
€1.67M - Cash at end of period
€3.11M - Free cash flow
€1.96M
Balance sheet
- Cash and cash equivalents
€3.11M - Cash and short-term investments
€3.11M - Total receivables
€4.68M - Inventory
€8.07M - Other current assets
€306.71K - Total current assets
€16.17M - Property, plant & equipment
€2.37M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€44.80K - Total non-current assets
€5.29M - Total assets
€21.45M - Accounts payable
€1.95M - Short-term debt
€584.99K - Other current liabilities
€1.12M - Total current liabilities
€3.66M - Long-term debt
€289.48K - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€289.48K - Total liabilities
€3.95M - Common stock
€53.42K - Retained earnings
-€27.07M - Other equity
€0.00 - Total equity
€17.50M - Total liabilities and shareholders' equity
€21.45M
Company information
- Market capitalization
€8.41M - Employees
147 - Enterprise Value
€7.57M
Company ratios
- Gross margin
-
10.2% Worse than peer group: 29.7% - EBITDA margin
-
6.0% Much better than peer group: -24.0% - EBIT margin
-
3.7% Much better than peer group: -20.0% - EBT margin
-
3.8% Much better than peer group: -24.5% - Net margin
-
1.5% Much better than peer group: -21.0% - ROE
-
4.0% Much worse than peer group: 1,194,013,909,135,923.4% - ROA
-
3.2% Much better than peer group: -551.7% - Asset turnover
-
218.3% Much better than peer group: 103.8% - FCF margin
-
3.4% Better than peer group: -6.6% - FCF yield
19.0% - Efficiency ratio
94.0% - Net sales per employee
-
€318.56K - Net income per employee
-
€4.74K